Reviewer’s report

Title: Coagulation profile of Sudanese children with homozygous sickle cell disease and the effect of treatment with omega-3 fatty acid on the coagulation parameters

Version: 0 Date: 18 Aug 2017

Reviewer: Binglan Yu

Reviewer's report:

Major comments:

1. The authors mentioned that hydroxyurea may cause potential organ damage in patients with renal impairment. Have the authors ever checked any markers for kidney function in the omega-3 treated group, such as serum creatinine, BUN?

2. In this study, the authors provide evidence that treatment with omega-3 fatty acids has similar effects as HU-treated group, on partially ameliorating SCD-associated chronic coagulopathic state. Have the authors considered combining omega-3 and hydroxyurea for treatment? Please comment on it.

Minor comments:

1. Please be consistent with "omega-3" throughout the manuscript, if no correct symbol can be selected. "n-3" is not correct for omega-3.

2. Table 1, there is typo in the 3rd column "HbS" should be "HbSS".

3. For figure 2 and 3, if P> 0.05, there is no need to indicate in the figure, but state it in the figure legend or text.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.